To industrially advantageously obtain the subject compound having high optical purity and useful for an anti-HIV medicine intermediate, etc., by reacting trans-(±)-2-bromoindan-1-ol with an ester in an organic solvent in the presence of a specific enzyme and separating a residual material.
A trans-(±)-2-bromoindan-1-ol expressed by formula I is reacted with an ester of formula II [R1 and R2 are each an alkyl, a (substituted) aryl, a (substituted) aralkyl] in an organic solvent in the presence of a lipase derived from a yeast or its recombinant and an optical isomer of a trans-(-)-(1R,2R) body of formula III or a trans-(+)-(1S,2S) body of formula IV is preferentially transesterified to obtain a trans-(-)-(1R,2R)-2-bromo-1-(acyloxy)indan of formula V or a trans-(+)-(1S,2S)-2-bromo-1-(acyloxy)indan of formula VI, then resultant product is separated to industrially advantageously obtain the objective residual compound.
OTSUTOMO SHINYA
SHIMOYAMADA MAKOTO
HARADA MASAKUNI
NAKANO SHIGERU
